Cagrilintide is a synthetic amylin analog engineered for extended receptor residence time, studied in research settings for amylin receptor (AMY receptor) signaling, satiety pathway analysis, and combination protocol applications alongside GLP-1 receptor agonists.

Amylin Biology and Receptor Pharmacology

Native amylin (islet amyloid polypeptide, IAPP) is co-secreted with insulin from pancreatic beta cells. Amylin receptors are heterodimeric complexes consisting of the calcitonin receptor (CTR) combined with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3), forming AMY1, AMY2, and AMY3 receptor subtypes. These receptors are expressed in the area postrema, hypothalamus, and nucleus accumbens — brain regions involved in satiety and food intake regulation research.

Cagrilintide vs. Native Amylin

Native amylin has a very short plasma half-life and a tendency toward aggregation and amyloid fibril formation — properties that limit its utility as a research tool compound. Cagrilintide incorporates structural modifications (fatty acid conjugation and sequence substitutions) that extend half-life and reduce aggregation propensity, making it a more stable research analog for amylin receptor studies.

Combination Protocol Research

The combination of cagrilintide with semaglutide (“CagriSema”) has been studied for amylin/GLP-1 receptor co-agonism. Research examines whether amylin receptor activation adds distinct pathway contributions to GLP-1 receptor signaling alone — particularly in central satiety circuitry and gastric motility research.

Research use only. Not for human or animal use.